Seraseq™ Breast CNV Mix, +6 copies
Ex Tax:
$1,069.00

Copy number variations (CNV) are genomic changes that lead to higher (amplification) or lower (loss) gene copies in comparison to a reference genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis.


Next-generation sequencing (NGS) can be used to determine CNVs across multiple genes in a sequencing run. However, without a widely adopted standard for CNV profiling, NGS assays may evaluate dosage for different targets using different “wet” and “dry” methods. In response, SeraCare has developed the first disease-specific CNV reference materials to support clinical labs performing NGS-based tumor profiling of cancer patient samples.


  • Single sample with three clinically-relevant CNVs (save acquisition and sequencing costs)
  • Develop, optimize, and validate your assay’s ability to detect a range of copy numbers (amplifications)
  • CNV targets precisely quantitated with digital PCR
  • Single well-characterized GM24385 human genomic DNA as background ‘wild-type’ material
  • Manufactured in GMP-compliant, ISO 13485-certified facilities